Japanese pharmaceutical company, Eisai Co., Ltd. has announced its partnership with neuroscience technology firm, Cogstate, Ltd. under which it has secured the global development and exclusive commercialization rights of all cognitive function tests made by Cogstate, including the ‘Cogstate Brief BatteryTM’ (CBB) for application in healthcare and other industries.
The two companies aim to further the development of CBB as a tool for individuals to self-assess brain performance to endorse healthy lifestyle choices and undertake preventative measures. The firms also aim at developing medical devices to aid healthcare professionals in making effective clinical decisions.
The global agreement between Cogstate and Eisai will enable in replicating many of the advancements already developed in Japan, which includes Eisai’s new digital tool named NouKNOWTM that uses CBB for self-assessment of brain performance (brain health). The pharmaceutical firm is currently seeking the possibility to develop a medical device using CBB in Japan.
Research indicates that in recent years major readjustments to lifestyle, such as a well-balanced diet, regular exercise and sleep, and social interaction, has led to the possibility of a decline in brain performance. Eisai claims that only few people are taking correct preventive actions or are performing self-checks of cognitive function.
As a result, in Japan, Eisai is developing a dementia platform, dubbed Easiit, with an aim of erasing these chasms. The center of this platform will be the brain-performance self-check tool NouKNOW and the Easiit App that focuses on contributing to the promotion of health practices through data visualization of brain and body health insights.
Reportedly, in the United States, Australia, Europe, Canada and New Zealand, the CBB has been adapted as a medical device under the named CognigramTM that has attained marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to advocate the diagnosis of dementia and MCI.
Source Credit: https://www.eisai.com/news/2020/news202066.html